- Home
- GLPG vs SDRL Comparison
GLPG vs SDRL Comparison
Compare GLPG & SDRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLPG | SDRL |
|---|---|---|
| Founded | 1999 | 2005 |
| Country | Belgium | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | GLPG | SDRL |
|---|---|---|
| Price | $32.44 | $33.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $31.33 | ★ $51.33 |
| AVG Volume (30 Days) | 110.6K | ★ 682.7K |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.55 |
| Revenue | $336,643,201.00 | ★ $1,307,000,000.00 |
| Revenue This Year | $3.61 | $6.84 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $60.23 |
| Revenue Growth | ★ 10.31 | N/A |
| 52 Week Low | $22.36 | $17.74 |
| 52 Week High | $37.78 | $40.20 |
Technical Indicators
Market Signals| Indicator | GLPG | SDRL |
|---|---|---|
| Relative Strength Index (RSI) | 58.84 | 63.46 |
| Support Level | $31.41 | $31.41 |
| Resistance Level | $31.98 | $33.69 |
| Average True Range (ATR) | 0.50 | 1.32 |
| MACD | 0.19 | 0.29 |
| Stochastic Oscillator | 86.33 | 94.56 |
Price Performance
Historical ComparisonAbout GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About SDRL Seadrill Limited
Seadrill Ltd is an offshore drilling contractor company. The company is engaged in providing offshore drilling services to the oil and gas industry. The primary business of the company is the ownership and operation of drillships, semi-submersible rigs, and jack-up rigs for operations in shallow to ultra-deepwater areas in both benign and harsh environments. The geographical segments of the company are the United States, Brazil, Angola, Norway, Canada and others. The company derives maximum revenue from the United States.